Rifan Muazin
Layla Zulfa
Nana
Asro
In a significant move to tackle one of the most stubborn sectors of industrial emissions, pharmaceutical heavyweights Sanofi, Opella, and UCB have joined forces with AstraZeneca to expand the "Clean Heat Program." Launched in December 2025, this collaborative initiative aims to drastically reduce reliance on fossil fuel-generated heat in industrial processes, marking a pivotal shift in how the healthcare sector approaches its environmental footprint.
By pooling their technical expertise and supply chain influence, these companies are addressing the massive energy demand required for drug formulation and production—processes that have historically relied on natural gas-powered steam boilers. With over 1,000 individual manufacturing sites already under the program’s umbrella, the initiative represents a concerted effort to scale low-carbon alternatives, including heat pumps, biomethane, and advanced electrification.
The Genesis of the Clean Heat Program
The Clean Heat Program was birthed from the recognition that individual corporate efforts, while commendable, were insufficient to shift the global industrial paradigm. AstraZeneca, which spearheaded the initiative, recognized that deep decarbonization requires collective action to drive market demand for clean thermal technologies.
Managed by consulting firm ERM and supply chain intelligence specialist Secaro, the program serves as a bridge between high-level sustainability commitments and on-the-ground execution. All founding partners—AstraZeneca, Sanofi, Opella, and UCB—have pledged science-based reduction targets that encompass their entire greenhouse gas (GHG) emissions inventory.
The initiative’s arrival comes at a critical time. As pharmaceutical companies strive to meet Scope 3 emissions targets—which include the activities of their suppliers—the need to standardize energy transition strategies across diverse geographical regions has become paramount. The program provides the necessary technical guidance and, in some instances, financing incentives to help suppliers navigate the complex transition from combustion to electrification.
Efficiency First: The Strategy Behind the Steam
For pharmaceutical manufacturers, steam is the lifeblood of production. It is used in sterilization, cleaning, and chemical synthesis, making it difficult to replace without compromising safety or quality. The Clean Heat Program operates under a "Efficiency First" mandate, emphasizing that the cleanest energy is the energy never consumed.
By optimizing processes through automation and modernizing heating, ventilation, and cooling (HVAC) systems, the partners are finding ways to reduce the baseline energy required before even considering the fuel source.
Case Studies in Operational Change
The practical application of these strategies is already yielding measurable results. Opella, the consumer healthcare giant behind brands like Icy Hot and Allegra, provides a blueprint for this transformation:
- Narita, Japan: The facility implemented a hybrid approach, replacing large boilers with three smaller-capacity units integrated with heat pumps. This strategic downsizing resulted in a 20% reduction in natural gas consumption.
- Lisieux, France, and Suzano, Brazil: Opella has successfully retrofitted these plants to utilize heat pumps for hot water production, feeding their air-treatment systems and moving away from traditional gas-powered boiler infrastructure.
These efforts underscore a broader philosophy: the transition is not merely about swapping fuel sources but about re-engineering industrial infrastructure to be inherently more efficient.
The Complexity of Accounting: The Merz Therapeutics Experience
While the technical transition is challenging, the "paperwork" of sustainability—carbon accounting—presents an equally daunting hurdle. Merz Therapeutics, a midsize pharmaceutical firm that electrified steam production at its Frankfurt headquarters, highlighted the hidden complexities of reporting these transitions.
Merz successfully eliminated 1.5 million kilowatt-hours of heating oil consumption, slashing their Scope 1 emissions by 250 tons of CO2 equivalent—a 46% reduction in their stationary emissions. However, the victory was nuanced. By moving to district heating, the company inadvertently shifted its carbon burden into the Scope 2 category (emissions from purchased energy).
"It illustrates how data availability and accounting methodology can affect the visibility of operational decarbonization measures within a corporate greenhouse gas inventory," explains Tatiana Kalashnikova, global sustainability lead for Merz. This reality check serves as a warning to the industry: decarbonization is not always a linear path, and the metrics used to track it must be as sophisticated as the technology being deployed.
The Role of Supply Chain Intelligence
A central pillar of the Clean Heat Program is its outreach to suppliers. According to Emily Prior, chief growth officer at Secaro, the knowledge gap across the supply chain is significant.
"We’ve got some sites that know exactly what they need to do to decarbonize their heat," Prior noted. "The blocker is financing. We’ve got others who will ask us, ‘What’s carbon, and why is my customer talking to me about it?’"
This disparity in readiness is why the initiative is so vital. By providing technical support and, in specific cases, facilitating financing, the program ensures that the transition is not limited to the largest players with the deepest pockets. The urgency of these discussions is further compounded by regional factors; for instance, Europe’s ongoing natural gas supply constraints have forced industrial energy transition to the top of investment agendas, creating a powerful economic tailwind for these clean energy projects.
Implications: A New Standard for Healthcare Manufacturing
The Clean Heat Program is more than a sustainability project; it is an attempt to standardize the decarbonization of industrial processes in a highly regulated, high-stakes industry. The implications are far-reaching:
- Setting a Sector Standard: As pharmaceutical companies face increasing scrutiny from investors and regulators regarding their environmental impact, this collaborative framework provides a credible, replicable model for other sectors that rely heavily on industrial heat.
- Driving Technology Adoption: By creating a demand signal for heat pumps, biomethane, and electrification, the initiative is encouraging technology providers to accelerate the development of industrial-scale solutions.
- Redefining Quality and Safety: Perhaps most importantly, the program proves that decarbonization does not have to come at the expense of quality. As Marissa Saretsky of Opella noted, the challenge is making low-carbon tech work at scale "while maintaining the quality, safety and reliability that are non-negotiable in healthcare."
Looking Forward: The Path to Net Zero
As the program matures, the focus will likely shift from initial site audits to large-scale infrastructure investments. The collaboration between AstraZeneca, Sanofi, Opella, and UCB demonstrates that the era of siloed sustainability is coming to an end.
The success of the Clean Heat Program will be measured by its ability to translate these ambitious goals into tangible, permanent shifts in how life-saving medicines are manufactured. With over 1,000 sites already involved, the foundation is set. The challenge remains in the technical nuances—the specific engineering requirements of a plant in Brazil versus one in Germany—and the ongoing work of bringing smaller suppliers into the fold.
In the long run, the pharmaceutical industry’s transition to clean heat could prove to be one of the most successful industrial decarbonization efforts of the decade. By treating energy efficiency as a core business function and carbon accounting as a vital metric of operational health, these companies are ensuring that the future of medicine is not only effective for the patient but sustainable for the planet.
As the industry moves toward 2030 and beyond, the Clean Heat Program will remain a vital case study in how collective action can overcome the inertia of traditional industrial practices, proving that even the most carbon-intensive processes can be transformed through innovation, collaboration, and a relentless commitment to efficiency.
Azzam Bilal Chamdy
